Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M H van der Ree

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
European Heart Journal|June 22, 2019
Playing by the rulesM H van der Ree, R A Scholte, P G Postema, et al.
Journal of Viral Hepatitis|June 21, 2017
HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-upF Stelma, M H van der Ree, L Jansen, et al.
Alimentary Pharmacology & Therapeutics|October 28, 2015
Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasmaM H van der Ree, A J van der Meer, A C van Nuenen, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
European Heart Journal|June 22, 2019
Playing by the rulesM H van der Ree, R A Scholte, P G Postema, et al.
Journal of Viral Hepatitis|June 21, 2017
HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-upF Stelma, M H van der Ree, L Jansen, et al.
Alimentary Pharmacology & Therapeutics|October 28, 2015
Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasmaM H van der Ree, A J van der Meer, A C van Nuenen, et al.
Pageof 1